Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Adult T-cell Leukemia/lymphoma in Japan

prnasiaJune 25, 2021

Tag: Chidamide , Chipscreen , Tucidinostat

PharmaSources Customer Service